Photoimmunotherapy for Brain Cancer
August 30, 2022 | Terry Sharrer
“PIT [photoimmunotherapy] is a light-mediated therapeutic approach, where a photosensitiser (PS) is conjugated to a highly specific monoclonal antibody (mAb), antibody fragment, or affibody molecule that has the ability to engage the selected target of interest. Near-infrared (NIR) light irradiation of the conjugate lead to ligand release reaction of IR700 and under normoxic conditions to the production of heat and reactive oxygen species (ROS) that, consequently, initiate target-selective cell death and stimulate inflammation, followed by vascular shutdown and tissue ischaemia [14,15,16].” MORE
Image Credit: bmcmedicine.biomedcentral.com